Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5
- 17 November 2015
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 39 (1) , 92-100
Abstract
OBJECTIVE To evaluate the efficacy and safety of basal insulin peglispro (BIL) versus insulin glargine in patients with type 2 diabetes (hemoglobin A1c [HbA1c] ≤9% [75 mmol/mol]) treated with basal insulin alone or with three or fewer oral antihyperglycemic medications. RESEARCH DESIGN AND METHODS This 52-week, open-label, treat-to-target study randomized patients (mean HbA1c 7.42% [57.6 mmol/mol]) to BIL (n = 307) or glargine (n = 159). The primary end point was change from baseline HbA1c to 26 weeks (0.4% [4.4 mmol/mol] noninferiority margin). RESULTS At 26 weeks, reduction in HbA1c was superior with BIL versus glargine (−0.82% [−8.9 mmol/mol] vs. −0.29% [−3.2 mmol/mol]; least squares mean difference −0.52%, 95% CI −0.67 to −0.38 [−5.7 mmol/mol, 95% CI −7.3 to −4.2; P < 0.001); greater reduction in HbA1c with BIL was maintained at 52 weeks. More BIL patients achieved HbA1c P < 0.001). With BIL versus glargine, nocturnal hypoglycemia rate was 60% lower, more patients achieved HbA1c P < 0.001), and total hypoglycemia rates were lower at 52 weeks (P = 0.03). At weeks 26 and 52, glucose variability was lower (P < 0.01), basal insulin dose was higher (P < 0.001), and triglycerides and aminotransferases were higher with BIL versus glargine (P < 0.05). Liver fat content (LFC), assessed in a subset of patients (n = 162), increased from baseline with BIL versus glargine (P < 0.001), with stable levels between 26 and 52 weeks. CONCLUSIONS BIL provided superior glycemic control versus glargine, with reduced nocturnal and total hypoglycemia, lower glucose variability, and increased triglycerides, aminotransferases, and LFC.Keywords
This publication has 29 references indexed in Scilit:
- Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect on Glucose MetabolismDiabetes, 2014
- Steady‐state pharmacokinetics and glucodynamics of the novel, long‐acting basal insulin LY2605541 dosed once‐daily in patients with type 2 diabetes mellitusDiabetes, Obesity and Metabolism, 2013
- Hepatoselectivity and the evolution of insulinDiabetes, Obesity and Metabolism, 2013
- Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitusDiabetes, Obesity and Metabolism, 2013
- Reproducibility of hepatic fat fraction measurement by magnetic resonance imagingJournal of Magnetic Resonance Imaging, 2012
- A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 DiabetesDiabetes Care, 2012
- Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetesCurrent Medical Research and Opinion, 2011
- Insulin Therapy for Type 2 DiabetesDiabetes Care, 2009
- When basal insulin therapy in type 2 diabetes mellitus is not enough—what next?Diabetes/Metabolism Research and Reviews, 2007
- Hepatic Removal of Insulin in Normal Man: Dose Response to Endogenous Insulin Secretion*The Journal of Clinical Endocrinology & Metabolism, 1983